HOPA 2019: Patients Receiving Cabozantinib for Metastatic Renal Cell Carcinoma May Not Tolerate the FDA-Approved Dose
Whether a lower median average daily dose leads to outcomes comparable to those in clinical trials needs to be determined.
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Renal Cell Carcinoma Center of Excellence
Visit our Renal Cell Carcinoma Center of Excellence for additional, in-depth coverage.